Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward
Abstract
:Simple Summary
Abstract
1. Introduction
2. Current Status of Antibiotic Research and Development
3. Trends in Push Funding
3.1. Country-Level Initiatives
3.1.1. US-Based National Initiatives
- National Institute of Allergy and Infectious Diseases (NIAID)
- Food and Drug Administration (FDA)
- Biomedical Advanced Research and Development Authority (BARDA)
- Department of Defense (DOD)
3.1.2. EU-Based National Initiatives
- Innovative Medicine Initiative-New Drugs for Bad Bugs (IMI-ND4BB)
- Innovfin Infectious Disease Facility (IDFF)
3.1.3. UK-Based National Initiatives
- Medical Research Council (MRC) and National Institute for Health and Care Research (NIHR)
3.2. Global Initiatives
3.2.1. US-Based Global Initiatives
- Antibacterial Resistance Leadership Group (ARLG)
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
3.2.2. EU-Based Global Initiatives
- Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- Global Antibiotic Research and Development Partnership (GARDP)
3.2.3. UK-Based Global Initiatives
- Department for International Development (DFID)
- Department for Business, Energy, and Industrial Strategy (BEIS)
- Department for Health and Social Care (DHSC)
- Wellcome
3.3. Pharmaceutical Industry Initiatives
3.3.1. Replenishing and Enabling the Pipeline for Anti-Infective Resistance (REPAIR) Impact Fund
3.3.2. AMR Action Fund
4. Challenges and the Way Forward
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Murray, C.J.; Ikuta, K.S.; Sharara, F.; Swetschinski, L.; Robles Aguilar, G.; Gray, A.; Han, C.; Bisignano, C.; Rao, P.; Wool, E.; et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef] [PubMed]
- Aminov, R.I. A Brief History of the Antibiotic Era: Lessons Learned and Challenges for the Future. Front. Microbiol. 2010, 1, 134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Renwick, M.J.; Brogan, D.M.; Mossialos, E. A Systematic Review and Critical Assessment of Incentive Strategies for Discovery and Development of Novel Antibiotics. J. Antibiot. 2016, 69, 73–88. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Outterson, K.; Rex, J.H. Evaluating For-Profit Public Benefit Corporations as an Additional Structure for Antibiotic Development and Commercialization. Transl. Res. 2020, 220, 182–190. [Google Scholar] [CrossRef] [PubMed]
- WHO. Antibacterial Preclinical Pipeline Review. Available online: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/who-antibacterial-preclinical-pipeline-review (accessed on 11 September 2022).
- Simpkin, V.L.; Renwick, M.J.; Kelly, R.; Mossialos, E. Incentivising Innovation in Antibiotic Drug Discovery and Development: Progress, Challenges and next Steps. J. Antibiot. 2017, 70, 1087–1096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cama, J.; Leszczynski, R.; Tang, P.K.; Khalid, A.; Lok, V.; Dowson, C.G.; Ebata, A. To Push or to Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority. ACS Infect. Dis. 2021, 7, 2029–2042. [Google Scholar] [CrossRef] [PubMed]
- Michael McCoy Achaogen Files for Bankruptcy. C&EN Glob. Enterp. 2019, 97, 17.
- Research Portfolio Online Reporting Tools (RePORT). Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). Available online: https://report.nih.gov/funding/categorical-spending#/ (accessed on 27 October 2022).
- NIAID’s Antibiotic Resistance Research Framework: Current Status and Future Directions. 2019. Available online: https://www.niaid.nih.gov/sites/default/files/AR2019.pdf (accessed on 27 October 2022).
- Types of Grant Programs. NIH Central Resource for Grants and Funding Information. Available online: https://grants.nih.gov/grants/funding/funding_program.htm (accessed on 27 October 2022).
- BEI Resources Repository. NIH: National Institute of Allergy and Infectious Diseases. Available online: https://www.niaid.nih.gov/research/bei-resources-repository (accessed on 1 November 2022).
- ARLG Biorepository. Antibacterial Resistance Leadership Group. Available online: https://arlg.org/laboratory-center-strain-access/ (accessed on 1 November 2022).
- National Database of Antibiotic Resistant Organisms (NDARO)—Pathogen Detection—NCBI. Available online: https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/ (accessed on 24 September 2022).
- Antimicrobial Resistance Information from FDA. FDA. Available online: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/antimicrobial-resistance-information-fda (accessed on 1 November 2022).
- Office of Infectious Diseases CARB Research Overview. 2022. Available online: https://www.fda.gov/es/media-base/150334/download (accessed on 24 September 2022).
- Office of Infectious Diseases Research Activities. FDA. Available online: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-infectious-diseases-research-activities (accessed on 27 October 2022).
- CDC & FDA Antimicrobial Resistance (AR) Isolate Bank. 2022. Available online: https://www.cdc.gov/drugresistance/resistance-bank/index.html (accessed on 27 October 2022).
- The CDC & FDA Antibiotic Resistance Isolate Bank Use of the AR Isolate Bank. Available online: https://www.fda.gov/medical-devices/in-vitro-diagnostics/cdc-fda-antibiotic-resistance-isolate-bank (accessed on 27 October 2022).
- Project BioShield. Progress in the War of Terror. Home Page. Available online: https://georgewbush-whitehouse.archives.gov/infocus/bioshield/ (accessed on 27 October 2022).
- Pandemic and All Hazards Preparedness Act. Administration for Strategic Preparedness and Response. Available online: https://aspr.hhs.gov/legal/pahpa/Pages/default.aspx (accessed on 27 October 2022).
- Antibiotic Resistance: Additional Federal Actions Needed to Better Determine Magnitude and Reduce Impact—U.S. Government Accountability Office. 2020. Available online: https://www.gao.gov/assets/gao-20-341.pdf (accessed on 27 October 2022).
- Houchens, C. The role of the biomedical advanced research and development authority (BARDA) in promoting innovation in antibacterial product development. 2017, Economics and Innovation. Available online: http://resistancecontrol.info/2017/the-role-of-the-biomedical-advanced-research-and-development-authority-barda-in-promoting-innovation-in-antibacterial-product-development/ (accessed on 29 October 2022).
- Visby Medical. Rapid Diagnostic for Gonorrhea Wins $19 Million Federal Prize Competition to Combat Antibiotic Resistance. 2020. Available online: https://www.visbymedical.com/news/press-release-rapid-diagnostic-for-gonorrhea-wins-19-million-federal-prize-competition-to-combat-antibiotic-resistance/ (accessed on 27 October 2022).
- Business Wire. The Medicines Company Awarded up to $ 132 Million to Develop Portfolio of New Antibiotics Targeting Drug-Resistant Infections under Strategic Partnership with BARDA. 2016. Available online: https://www.businesswire.com/news/home/20160921005135/en/The-Medicines-Company-Awarded-up-to-132-Million-to-Develop-Portfolio-of-New-Antibiotics-Targeting-Drug-Resistant-Infections-under-Strategic-Partnership-with-BARDA (accessed on 27 October 2022).
- Drusano, G.L.; Shields, R.K.; Mtchedlidze, N.; Nguyen, M.H.; Clancy, C.J.; Vicciarelli, M.; Louie, A. Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella Pneumoniae in a Hollow Fiber Infection Model. Antimicrob. Agents Chemother. 2019, 63, e00462-19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fierce Biotech. Achaogen Awarded $60M Contract Option by BARDA for the Clinical Development of Plazomicin Media Contact: Or Investor Contact. 2013. Available online: https://www.fiercebiotech.com/biotech/achaogen-awarded-60m-contract-option-by-barda-for-clinical-development-of-plazomicin (accessed on 27 October 2022).
- Berkrot, B. Tetraphase Antibiotic May Reach up to $ 700 Million in Annual Sales: CEO. 2017, pp. 22–24. Available online: https://www.reuters.com/article/us-tetraphase-outlook-ceo-idINKBN15O157 (accessed on 29 October 2022).
- Defense Threat Reduction Agency Awards $75M for Antibiotic Drug Development—Global Biodefense. 2021. Available online: https://globalbiodefense.com/2021/01/26/defense-threat-reduction-agency-awards-75m-for-antibiotic-drug-development/ (accessed on 27 October 2022).
- Innovative Medicines Initiative, Europe’s Partnership for Health, History—The IMI Story So Far. Available online: https://www.imi.europa.eu/about-imi/history-imi-story-so-far (accessed on 27 October 2022).
- Innovative Medicines Initiative, Europe’s Partnership for Health, About IMI. Available online: https://www.imi.europa.eu/about-imi (accessed on 19 October 2022).
- Innovative Medicines Initiative, Europe’s Partnership for Health, ND4BB: New Drugs for Bad Bugs. Available online: https://www.imi.europa.eu/projects-results/project-factsheets/nd4bb (accessed on 19 October 2022).
- New Drugs for Bad Bugs. The Innovative Medicines Initiative Response to Antimicrobial Resistance Drugs. 2017. Available online: https://www.imi.europa.eu/sites/default/files/uploads/documents/projects/IMI_AMR_2017_LR.pdf (accessed on 19 October 2022).
- The Right Prevention and Treatment for the Right Patient at the Right Time. Strategic Research Agenda for Innovative Med-icines Initiative 2. Available online: https://www.imi.europa.eu/sites/default/files/uploads/documents/About-IMI/research-agenda/IMI2_SRA_March2014.pdf (accessed on 25 October 2022).
- InnovFin Infectious Diseases—European Investment Bank. 2020. Available online: https://www.eib.org/attachments/thematic/innovfin_infectious_diseases_en.pdf (accessed on 25 October 2022).
- Corporate Report. Global AMR Innovation Fund Annual Review: 2017 to 2019. Available online: https://www.gov.uk/government/publications/global-amr-innovation-fund-annual-review-2017-to-2019/global-amr-innovation-fund-annual-review-2017-to-2019 (accessed on 25 October 2022).
- UK Research and Innovation. Medical Research Council. Types of Funding We Offer. Available online: https://www.ukri.org/councils/mrc/guidance-for-applicants/types-of-funding-we-offer/ (accessed on 25 October 2022).
- UK Research and Innovation. Medical Research Council. Types of Research Organisations. Available online: https://www.ukri.org/councils/mrc/guidance-for-applicants/check-if-you-are-eligible-for-funding/1-1-types-of-research-organisations/ (accessed on 25 October 2022).
- National Institute for Health and Care Research (NIHR) Who We Are. Available online: https://www.nihr.ac.uk/about-us/who-we-are/ (accessed on 25 October 2022).
- National Institute for Health and Care Research (NIHR) Tackling Antimicrobial Resistance. Available online: https://www.nihr.ac.uk/documents/tackling-antimicrobial-resistance/31214 (accessed on 25 October 2022).
- NIHR Announces Nearly £800m to Turn Research into New Treatments. 2022. Available online: https://www.nihr.ac.uk/news/nihr-announces-nearly-800m-to-turn-research-into-new-treatments/31653 (accessed on 25 October 2022).
- Doi, Y.; Bonomo, R.A.; Hooper, D.C.; Kaye, K.S.; Johnson, J.R.; Clancy, C.J.; Thaden, J.T.; Stryjewski, M.E.; Van Duin, D. Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Re-sistance Leadership Group. Clin. Infect. Dis. 2017, 64, S30–S35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- US National Institutes for Health (NIH) Renews Funding for the Antibacterial Resistance Leadership Group. News Releases 2019. Available online: https://www.nih.gov/news-events/news-releases/nih-renews-funding-antibacterial-resistance-leadership-group#:~:text=As%20antibiotic%2Dresistant%20bacteria%20become,Resistance%20Leadership%20Group%20(ARLG) (accessed on 28 October 2022).
- Alm, R.A.; Gallant, K. Innovation in Antimicrobial Resistance: The CARB-X Perspective. ACS Infect. Dis. 2020, 6, 1317–1322. [Google Scholar] [CrossRef] [PubMed]
- CARB-X. Preparing the World against Antibiotic-Resistant Bacteria. 2021. Available online: https://carb-x.org/wp-content/uploads/2021/10/CarbX_AR_20-21.pdf (accessed on 28 October 2022).
- CARB-X Funding Partners. CARB-X Is a Global Non-Profit Partnership. Available online: https://carb-x.org/partners/funding-partners/#:~:text=CARB%2DX%20is%20funded%20by,Ministry%20of%20Education%20and%20Research%20 (accessed on 28 October 2022).
- CARB-X Complete Portfolio, as of 8/16/22. Available online: https://carb-x.org/wp-content/uploads/2022/08/CARB-X-Pipeline-2022.08.16.pdf (accessed on 28 October 2022).
- CARB-X Portfolio Pipeline. Supporting a Diverse Portfolio. Available online: https://carb-x.org/portfolio/portfolio-pipeline/ (accessed on 28 October 2022).
- CARB-X Global Accelerator Network. Available online: https://carb-x.org/partners/global-accelerator-network/ (accessed on 28 October 2022).
- CARB-X World’s Leading Funders of Antibacterial Research Provide Guidance on Stewardship and Access in the Fight against Antibiotic-Resistant Bacteria. Available online: https://carb-x.org/carb-x-news/worlds-leading-funders-of-antibacterial-research-provide-guidance-on-stewardship-and-access-in-the-fight-against-antibiotic-resistant-bacteria/ (accessed on 28 October 2022).
- JPIAMR. Ten Years of Achievements. Global Coordination of Antimicrobial Resistance Research 2022.. Available online: https://www.jpiamr.eu/app/uploads/2022/01/JPIAMR-10-years-of-achievements-folder.pdf (accessed on 28 October 2022).
- JPIAMR Implementation Plan 2021–2023. Available online: https://www.jpiamr.eu/app/uploads/2021/06/JPIAMR-Implementation-Plan-2021-2023.pdf (accessed on 18 October 2022).
- Savic, M.; Årdal, C. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics. J. Law Med. Ethics 2018, 46, 9–24. [Google Scholar] [CrossRef] [PubMed]
- JPIAMR. Strategic Research and Innovation Agenda on Antimicrobial Resistance 2021. Available online: https://www.jpiamr.eu/app/uploads/2021/06/JPIAMR_SRIA_2021.pdf (accessed on 21 October 2022).
- EDCTP. Our Mission and Vision. Available online: http://www.edctp.org/about-us/#:~:text=Our%20mission%20and%20vision,suitable%20and%20affordable%20medical%20interventions (accessed on 21 October 2022).
- EDCTP2 Portfolio: Clinical Research Capacity 2020. Available online: https://www.edctp.org/web/app/uploads/2020/10/EDCTP-case-studies-2020-CSA-Capacity-Development-projects.pdf (accessed on 21 October 2022).
- EDCTP. Frequently Asked Questions—Global Health EDCTP3 Joint Undertaking. Available online: http://www.edctp.org/frequently-asked-questions-global-health-edctp3-joint-undertaking/ (accessed on 21 October 2022).
- First EDCTP3 Calls Are Now Open. LINQ Management. Available online: https://linq-management.com/news/first-edctp3-calls-are-now-open.html (accessed on 21 October 2022).
- Global Antibiotic Research and Development Partnership (GARDP). About GARDP. Available online: https://gardp.org/who-we-are/about-gardp/ (accessed on 22 September 2022).
- GARDP. In Focus: Discovery & Exploratory Research 2018. Available online: https://gardp.org/uploads/2022/08/GARDP-In-Focus-Discovery-Exploratory_2022.pdf (accessed on 22 September 2022).
- GARDP. GARDP and Penta Partner to Accelerate the Development of Children’s Antibiotics to Tackle AMR. Available online: https://www.gardp.org/news-resources/gardp-penta-partner-accelerate-development-of-children-antibiotics/ (accessed on 28 October 2022).
- GARDP. In Focus: Making Children’s Antibiotics a Priority. Available online: https://gardp.org/news-resources/in-focus-childrens-antibiotics/?_ga=2.120053517.423490250.1666938063-1690401718.1651766784 (accessed on 28 October 2022).
- GARDP. GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhoea. Available online: https://www.gardp.org/news-resources/gardp-and-entasis-therapeutics-initiate-global-phase-3-trial-of-zoliflodacin-a-first-in-class-oral-antibiotic-for-the-treatment-of-gonorrhoea/ (accessed on 28 October 2022).
- GARDP. GARDP Signs MOU with Swiss Biotech BioVersys 2020. Available online: https://www.bioversys.com/gardp-signs-mou-with-swiss-biotech-bioversys-ag/#:~:text=The%20Global%20Antibiotic%20Research%20and,antibiotics%20for%20serious%20bacterial%20infections (accessed on 28 October 2022).
- GARDP Serious Bacterial Infections 2021. Available online: https://www.gardp.org/programme/serious-bacterial-infections/ (accessed on 28 October 2022).
- GARDP. REVIVE: Advancing Antimicrobial R&D. Available online: https://revive.gardp.org/ (accessed on 1 November 2022).
- UK Collaborative on Development Research. Antimicrobial Resistance in International Development: UK Research Funding Landscape. 2019. Available online: https://www.ukcdr.org.uk/wp-content/uploads/2019/09/UKCDR-Report-AMR-in-Int-Dev_UK-research-funding-landscape-2019_high-res.pdf (accessed on 28 October 2022).
- Economic and Social Research Council. £4.5 Million Newton Fund to Tackle Antimicrobial Resistance. Official Press Release; 2016. Available online: https://www.wired-gov.net/wg/news.nsf/articles/4.5+million+Newton+Fund+to+tackle+antimicrobial+resistance+10082016162000?open (accessed on 23 December 2022).
- Wellcome. History of Wellcome? Available online: https://wellcome.org/who-we-are/history-wellcome (accessed on 28 October 2022).
- Wellcome. Infectious Disease: What We Do? Available online: https://wellcome.org/what-we-do/infectious-disease (accessed on 1 November 2022).
- Jinks, T. We’re Backing the AMR Action Fund—This Is What It Means for Antibiotic Innovation. 2021. Available online: https://wellcome.org/news/were-backing-amr-action-fund-what-it-means-antibiotic-innovation (accessed on 1 November 2022).
- REPAIR Impact Fund. About. Available online: https://www.repair-impact-fund.com/about/ (accessed on 1 November 2022).
- REPAIR Impact Fund. Portfolio. Available online: https://www.repair-impact-fund.com/portfolio/ (accessed on 1 November 2022).
- AMR Action Fund. About Us. Available online: https://www.amractionfund.com/about#our-mission (accessed on 1 November 2022).
- WHO. Pipeline of Antibacterial Products in Clinical Development. Available online: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens (accessed on 31 October 2022).
- BEAM Alliance. March 2022. Available online: https://beam-alliance.eu/wp-content/uploads/2022/09/2022-03-18-beam-leaflet.pdf (accessed on 31 October 2022).
- BEAM Alliance Reflection Paper on the AMR Action Fund. 2020. Available online: https://beam-alliance.eu/wp-content/uploads/2020/09/amractionfund_reflection-paper.pdf (accessed on 31 October 2022).
- BEAM Alliance Position Paper. 2017. Available online: https://anr.fr/fileadmin/documents/2018/BEAMAlliancePositionPaper.pdf (accessed on 31 October 2022).
- BARDA and Vedanta Biosciences Partner for Phase 3 Clinical Trial of VE303 as a Potential Treatment for C. Difficile Bacterial Infections. 2021. Available online: https://www.medicalcountermeasures.gov/newsroom/2021/vedanta/ (accessed on 31 October 2022).
- Vedanta Biosciences Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. Difficile Infection and Exercise of $23.8 Million Option by BARDA. 2021. Available online: https://www.vedantabio.com/news-media/press-releases/detail/2805/vedanta-announces-positive-topline-phase-2-data-for-ve303 (accessed on 31 October 2022).
- AMR Control Overcoming global antimicrobial resistance. The Global AMR R&D Hub—Enhancing the International Coordination of Antimicrobial Resistance Research and Development. Available online: http://resistancecontrol.info/2019-4/the-global-amr-rd-hub-enhancing-the-international-coordination-of-antimicrobial-resistatance-research-and-development/ (accessed on 31 October 2022).
- G20 Leaders’ Declaration Shaping an Interconnected World. 2017. Available online: http://www.g20.utoronto.ca/2017/2017-G20-leaders-declaration.pdf (accessed on 31 October 2022).
- Global AMR R&D Hub. Annual Report 2021: The Global AMR R&D Funding Landscape. 2021. Available online: https://globalamrhub.org/wp-content/uploads/2021/12/Annual-Report_Final_10122021.pdf (accessed on 31 October 2022).
- Global AMR R&D Hub. Dynamic Dashboard. Available online: https://dashboard.globalamrhub.org/ (accessed on 31 October 2022).
Initiatives | Year | R&D Stage | Institutions | Countries | |
---|---|---|---|---|---|
National Initiatives | |||||
US | |||||
NIAID | 2008 | Early-to-late-stage | Research organizations, SMEs | US | |
BARDA | 2010 | Majorly late-stage | SMEs, big pharmaceuticals | US, funds globally through CARB-X | |
DOD | 2012 | Early-stage | Research organizations | US | |
FDA | 2014 | Regulatory science research | Industries and research organizations | US | |
EU | |||||
IMI-ND4BB | 2011 | Early-stage to market | Industries and research organizations | EU member states and FP7-associated countries | |
IDFF | 2014 | Late-stage | Industries and research organizations | 28 EU member states and 17 countries associated with Horizon 2020 | |
UK | |||||
NIHR | 2008 | Early-to-late-stage | Research organizations | UK (England-centric) | |
MRC | 2013 | Majorly early-stage | Industries and research organizations | UK | |
Global Initiatives | |||||
US-based | |||||
NIAID’s ARLG | 2013 | Late-stage | Industries and research organizations | Collaboration with 19 countries | |
CARB-X | 2016 | Early-stage to Phase 1 trials | Industries and research organizations | Global collaboration | |
EU based | |||||
EDCTP | 2003 | Late-stage | Industries and research organizations | Europe-Africa initiative | |
JPIAMR | 2011 | Early-stage | Research organizations | Collaboration with 29 member countries and European Commission | |
GARDP | 2016 | Pipeline coordinator, Early-stage to market | Industries and research organizations | Global collaboration | |
UK based | |||||
Wellcome | 2013 | Early- to late-stage | Industries and research organizations | Global collaboration, Funds CARB-X and AMR Action Fund | |
DHSC’s GAMRIF | 2014 | Majorly Early-stage | Industries and research organizations | Funds JPIAMR, CARB-X | |
BEIS’s Newton Fund | 2014 | Early-stage | Research organizations | UK partnership with 16 countries inAsia, Africa, and Latin America | |
BEIS’s GCRF | 2015 | Early- to late-stage | Industries and research organizations | UK partnership with developing countries | |
DFID’s PDP | 2017 | Early- to late-stage | Non-profit partnerships | Collaboration with global organizations such as FIND, GARDP, etc. | |
Pharmaceutical funding | |||||
REPAIR Impact Fund | 2018 | Early-stage to Phase 1 trials | Start-ups, early-stage companies, and corporate spinouts | Europe and US | |
AMR Action Fund | 2020 | Late-stage | Pharmaceutical companies | Global collaboration |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wasan, H.; Singh, D.; Reeta, K.H.; Gupta, Y.K. Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward. Biology 2023, 12, 101. https://doi.org/10.3390/biology12010101
Wasan H, Singh D, Reeta KH, Gupta YK. Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward. Biology. 2023; 12(1):101. https://doi.org/10.3390/biology12010101
Chicago/Turabian StyleWasan, Himika, Devendra Singh, K.H. Reeta, and Yogendra Kumar Gupta. 2023. "Landscape of Push Funding in Antibiotic Research: Current Status and Way Forward" Biology 12, no. 1: 101. https://doi.org/10.3390/biology12010101